Werewolf Therapeutics, Inc. (HOWL) NASDAQ

2.05

+0.13(+6.77%)

Updated at October 03 04:00PM

Currency In USD

Werewolf Therapeutics, Inc.

Address

1030 Massachusetts Avenue

Watertown, MA 02138

United States of America

Phone

617 952 0555

Sector

Healthcare

Industry

Biotechnology

Employees

46

First IPO Date

April 30, 2021

Key Executives

NameTitlePayYear Born
Dr. Daniel J. Hicklin Ph.D.Founder, Chief Executive Officer, President, Secretary & Director985,7321964
Dr. Chulani Karunatilake Ph.D.Chief Technology Officer343,4311959
Mr. Timothy W. Trost CPAChief Financial Officer, Treasurer & Assistant Secretary678,6751958
Dr. Randi Isaacs M.D.Chief Medical Officer722,8451956
Mr. Steven H. Bloom R.Ph.Chief Business Officer01961
Dr. William Winston Ph.D.Senior Vice President of Research0N/A

Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.